Article Information
Published By
Online ISSN
History
- Received August 26, 2022
- Accepted October 16, 2022
- Published online November 10, 2022.
Copyright & Usage
Copyright ©The authors 2022 This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Hunter Gillies1⇑,
- Ralph Niven1,
- Benjamin T. Dake1,
- Murali M. Chakinala2,
- Jeremy P. Feldman3,
- Nicholas S. Hill4,
- Marius M. Hoeper5,
- Marc Humbert6,
- Vallerie V. McLaughlin7 and
- Martin Kankam8
- 1Aerovate Therapeutics, Waltham, MA, USA
- 2Washington University School of Medicine, St. Louis, MO, USA
- 3Arizona Pulmonary Specialists, Phoenix, AZ, USA
- 4Pulmonary Critical Care & Sleep Division, Tufts Medical Center, Boston, MA, USA
- 5Respiratory Medicine, Hannover Medical School and German Centre of Lung Research, Hannover, Germany
- 6Université Paris–Saclay, INSERM, Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin Bicêtre, France
- 7University of Michigan, Ann Arbor, MI, USA
- 8Altasciences Clinical Kansas, Inc., Overland Park, KS, USA
- Corresponding author: Hunter Gillies (hgillies{at}aerovatetx.com)
Funding
Aerovate Therapeutics
Article usage
Altmetrics
Vol 9 Issue 1
Table of Contents
AV-101, a Novel Inhaled Dry Powder Formulation of Imatinib, in Healthy Adult Participants: A Phase 1 Single and Multiple Ascending Dose Study
